Zimmer Biomet (ZBH) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.5B

Revenue (quarter)

$2.2B

Revenue growth (year over year)

+4.80%

Gross profit (trailing twelve months)

$5.9B

Gross margin

69.87%

Net income (trailing twelve months)

$807.0M

Net income (quarter)

$199.6M

Net income growth (year over year)

+30.12%

Net margin

9.48%

Return on equity

6.42%

EPS (trailing twelve months)

$4.12

Book value per share

$66.23

P/E (trailing twelve months)

21.77

Price to book

1.39

Debt to assets

44.59%

Payout ratio

26.96%

Dividend yield

1.06%

Company profile

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

• Is Zimmer Biomet (ZBH) profitable?

  Yes. Zimmer Biomet earned $807.0M in net income over the trailing twelve months, a net margin of 9.48%.

• How much revenue does Zimmer Biomet (ZBH) make?

  Zimmer Biomet generated $8.5B in revenue over the trailing twelve months, up 4.80% year over year.

• What is ZBH's P/E ratio?

  Zimmer Biomet trades at 21.8 times trailing twelve-month earnings, on an EPS of $4.12.

• How do I buy stock in Zimmer Biomet (ZBH)?

  ZBH trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.